Biosimilars for Retinal Vascular Diseases

Upcoming patent expiries for anti-vascular endothelial growth factor (VEGF) therapies for retinal vascular diseases hold promise for expanded access to these extremely useful therapies through the introduction of biosimilars. However, the environment is extremely competitive and it is critical for biosimilar sponsors to make well-informed choices in several key areas, including study design, selection of sites and geographies and barriers to participation. In this White Paper, IQVIA experts share their insights on how the biosimilar development process can be optimized.